MediciNova to Participate in the Maxim Growth Summit
Globe Newswire•06/10/2026•06:00 ET
0
Key Highlights
- ➤MediciNova (MNOV) management to attend Maxim Growth Summit October 12-14, 2026
- ➤MN-166 in late-stage ALS and DCM trials; Phase 3-ready for progressive MS
- ➤MN-166 being evaluated in Phase 2 Long COVID and substance dependence trials
- ➤MN-001 Phase 2 NAFLD trial ongoing after IPF Phase 2 evaluation
Expert Statements
David H. Crean, Chief Business Officer of MediciNova, Inc.
“No direct quote or clearly attributed statement from David H. Crean appears in the article.”
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event.
Investors interested in scheduling a meeting with MediciNova management should contact their Maxim representative or visit here for more information.
Get started
Create a free account to read the full story.